Lars Peter Brunse moves up the ladder at Ferring

5 July 2017
ferringbig

Privately-held Swiss drugmaker Ferring Pharmaceuticals says that Lars Peter Brunse has been appointed executive vice president and chief production officer, and made a member of the Ferring executive board, effective immediately.

Mr Brunse joined Ferring as associate director technical operations in 2000 and was rapidly promoted to SVP, technical operations and logistics. He has led the expansion of Ferring's manufacturing capability with the development of an additional nine state-of-the-art production sites, and extended the company's product supply network from approximately 500 employees in the year 2000 to over 1,600 today.

"Lars Peter has been instrumental in expanding Ferring's production capacity, most recently through the successful completion of new sites in the US and India," said Michel Pettigrew, president of the executive board and chief operating officer, Ferring Pharmaceuticals, adding: "His team-focused leadership style has been extremely effective in building a strong product supply organisation, and his experience makes him uniquely qualified for this new role."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology